ReviewMarine drugs2017
Marine Sponge Natural Products with Anticancer Potential: An Updated Review.
Review in Marine drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 156 citations in OpenAlex.
- Wildlife Diseases: Pathology and Diagnostic Investigation.Animals : an open access journal from MDPI · 2026Article
- Nudibranch Cadlina rumia discriminates waterborne cues to find prey and conspecifics and avoid threats.BMC zoology · 2026Article
- Ethanolic extracts from deep marine sponges: A new frontier in antibacterial discovery from the Jordanian Gulf of Aqaba.Biomedical reports · 2026Article
- Anticancer and Antimicrobial Activity ofMolecules (Basel, Switzerland) · 2026Article
- Methyl linolenate suppresses the growth and proliferation of Ehrlich ascites carcinoma (EAC) cells by inducing intrinsic mitochondrial apoptosis.EXCLI journal · 2026Article
- Mechanistic Investigation of Adociaquinone and Xestoquinone Derivatives in Breast Cancer Cells.Marine drugs · 2025Article
- Enhancing cancer treatment with marine algae-derived bioactive chemicals: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- In-vitro and bioinformatic studies of bioactive compounds from Oceanimonas sp. JM-AZM31 and Lysinibacillus fusiformis JM-AZM37 of sponge-associated marine bacteria from a mangrove habitat in Southeast Sulawesi.Journal, genetic engineering & biotechnology · 2025Article
- New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma.Marine drugs · 2025Article
- Multifaceted Marine Peptides and Their Therapeutic Potential.Marine drugs · 2025Review
- Therapeutic potential of morpholine-based compounds in neurodegenerative diseases: SAR insights and analysis.Future medicinal chemistry · 2025Review
- Innovative vibriosis control in open aquaculture: Paratapes undulata as a sustainable growth and resistance enhancer in red tilapia.Scientific reports · 2025Article
- Vertical Cancer Transmission via Asexual Fragmentation and Associated Cancer Prevalence.Evolutionary applications · 2025Article
- Uncovering Novel Anti-Lung Cancer Compounds: Insights from Marine Sponge-Derived Agents: A Bibliometric Review.Iranian journal of medical sciences · 2025Review
- Bioassay-Guided Procedure Coupled with HR-ESIMS Dereplication for Isolation of Antiproliferative Bromo-Tyramine Derivative fromMarine drugs · 2025Article
- Article
- Two Novel Compounds Isolated from the Marine Fungal Symbiont ofJournal of experimental pharmacology · 2025Article
- Structure-Activity Relationship Study of Biselyngbyolide B Reveals Mitochondrial Fission-Induced Cytotoxicity in Cancer.ACS medicinal chemistry letters · 2024Article
- Aaptamine-rich Fraction from the Indonesian Marine Sponge, Aaptos suberitoides, Exhibits a Cytotoxic Effect on DLD-1 Colorectal Cancer Cells.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- The Characterization and Cytotoxic Evaluation ofMarine drugs · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the huge investment into research and the significant effort and advances made in the search for new anticancer drugs in recent decades, cancer cure and treatment continue to be a formidable challenge. Many sources, including plants, animals, and minerals, have been explored in the oncological field because of the possibility of identifying novel molecular therapeutics. Marine sponges are a prolific source of secondary metabolites, a number of which showed intriguing tumor chemopreventive and chemotherapeutic properties. Recently, Food and Drug Administration-approved drugs derived from marine sponges have been shown to reduce metastatic breast cancer, malignant lymphoma, and Hodgkin's disease. The chemopreventive and potential anticancer activity of marine sponge-derived compounds could be explained by multiple cellular and molecular mechanisms, including DNA protection, cell-cycle modulation, apoptosis, and anti-inflammatory activities as well as their ability to chemosensitize cancer cells to traditional antiblastic chemotherapy. The present article aims to depict the multiple mechanisms involved in the chemopreventive and therapeutic effects of marine sponges and critically explore the limitations and challenges associated with the development of marine sponge-based anticancer strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.